People: Oncothyreon Inc (ONTY.O)

Summary

Name	Age	Since	Current Position
Christopher Henney	72	2006	Non-Executive Independent Chairman of the Board
Robert Kirkman	64	2006	President, Chief Executive Officer, Director
Julia Eastland	48	2010	Chief Financial Officer, Vice President - Corporate Development, Secretary
Gary Christianson	58	2007	Chief Operating Officer
Scott Peterson	51	2012	Chief Scientific Officer, Vice President - Research & Development
Diana Hausman	49	2012	Chief Medical Officer, Vice President - Clinical Development
Richard Jackson	73	2003	Independent Director
Daniel Spiegelman	54	2008	Independent Director
W. Vickery Stoughton	67	1997	Independent Director
Douglas Williams	54	2009	Independent Director
Julie Rathbun			IR Officer

» Insider Trading

Biographies

Name	Description
Christopher Henney	Dr. Christopher S. Henney is Non-Executive Independent Chairman of the Board of Oncothyreon Inc. He is a member of board of directors since March 2005. Dr. Henney is a member of compensation and corporate governance and nominating committees. From 1995 to 2003, Dr. Henney was chairman and chief executive officer of Dendreon Corporation, a publicly-traded biotechnology company that he co-founded and from 2003 to 2005 continued as executive chairman. Dr. Henney was also a co-founder of Immunex Corporation and ICOS Corporation, both publicly-traded biotechnology companies. Dr. Henney’s qualifications for membership on the board of directors include his roles as co-founder of Dendreon, Immunex and ICOS, as well as his membership on the boards of directors of several development-stage biotechnology companies. Through his experience in working with biotechnology companies from founding until commercialization of their product candidates, Dr. Henney provides board of directors with insights into the strategic, operational and clinical development aspects of the company. Dr. Henney currently serves as vice-chairman of the board of directors of Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceuticals company, and chairman of the board of directors of Anthera Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Henney was the chairman of SGX Pharmaceuticals, Inc., a biotechnology company acquired by Eli Lilly in 2008, and a member of the board of directors of AVI BioPharma, Inc., a biopharmaceuticals company, until June 2010. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham, England, where he obtained his D.Sc. for contributions in the field of immunology. Dr. Henney is a former professor of immunology and microbiology and has held faculty positions at Johns Hopkins University, the University of Washington and the Fred Hutchinson Cancer Research Center.
Robert Kirkman	Dr. Robert L. Kirkman is President, Chief Executive Officer, Director of Oncothyreon Inc. From 2005 to 2006, Dr. Kirkman was acting president and chief executive officer of Xcyte Therapies, Inc., which concluded a merger with Cyclacel Pharmaceuticals, Inc., both development stage biopharmaceuticals companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was chief business officer and vice president of Xcyte. From 1998 to 2003, Dr. Kirkman was vice president, business development and corporate communications of Protein Design Labs, Inc., a biopharmaceuticals company. Dr. Kirkman’s qualifications for membership on the board of directors include his previous experience at development stage biotechnology companies and his position as president and chief executive officer. Dr. Kirkman’s scientific understanding along with his corporate vision and operational knowledge provide strategic guidance to management team and board of directors. Dr. Kirkman holds an M.D. degree from Harvard Medical School and a B.A. in economics from Yale University.
Julia Eastland	Ms. Julia Marie Eastland is Chief Financial Officer, Vice President - Corporate Development, Secretary of Oncothyreon Inc. Ms. Eastland was appointed as chief financial officer and vice president, corporate development in August 2010 and was appointed as secretary in October 2010. From February 2006 to 2010, Ms. Eastland served as chief financial officer and vice president Finance and Operations of VLST Corporation, a privately held biotechnology company. From 2000 to 2005, Ms. Eastland held various finance positions at Dendreon Corporation, a publicly-traded biotechnology company, most recently as the vice president of strategic planning. Prior to Dendreon, Ms. Eastland worked for Amgen, Inc. as area finance manager and assistant controller for its Colorado operations. Ms. Eastland has worked as director of finance and planning for Encore Media Group, international finance and business manager and senior financial analyst for SCIENCE Magazine and financial manager for the Discovery Channel. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
Gary Christianson	Mr. Gary Christianson is Chief Operating Officer of Oncothyreon Inc., since July 2007. From 2005 to 2007, Mr. Christianson was site director for the Biologics Unit of GlaxoSmithKline plc, a global healthcare company. From 1999 to 2003, Mr. Christianson was vice president, technical operations at Corixa Corp., a biopharmaceutical and biotechnology company, and from 2003 to 2005, he was promoted to general manager of the Hamilton, Montana site in addition to his duties as vice president. From 1987 to 1999, Mr. Christianson held various positions at RIBI ImmunoChem Research, Inc., a biopharmaceuticals company. Mr. Christianson received a B.S. in mechanical engineering technology from Montana State University and is a licensed and board certified professional engineer.
Scott Peterson	Dr. Scott Peterson is Chief Scientific Officer, Vice President - Research & Development of Oncothyreon Inc., effective June 21, 2012. From 2007 until 2009 Dr. Peterson served as director and department head, Oncology Research at Zymogenetics, Inc., a biopharmaceutical company. From 1999 to 2007, Dr. Peterson held a variety of positions at ICOS Corporation, a biopharmaceutical company. Dr. Peterson received his Ph.D. in chemistry (biochemistry) from the University of Colorado, Boulder and holds a B.S. in biology from Washington State University.
Diana Hausman	Dr. Diana Hausman is Chief Medical Officer, Vice President - Clinical Development of Oncothyreon Inc. Dr. Hausman was appointed vice president, clinical development in August 2009 and Chief Medical Officer in January 2012. From 2005 to 2009, Dr. Hausman served in a variety of positions at Zymogenetics, Inc., a biopharmaceutical company, most recently as senior director, clinical research. From 2002 until 2009, Dr. Hausman served as senior associated medical director at Berlex Inc., a biopharmaceutical company. Dr. Hausman received her A.B. in Biology from Princeton University, and her M.D. from the University of Pennsylvania School of Medicine. She was trained in internal medicine and hematology/oncology at the University of Washington and is board certified in medical oncology.
Richard Jackson	Dr. Richard L. Jackson is an Independent Director of Oncothyreon Inc. Dr. Jackson is the chairman of compensation committee and a member of corporate governance and nominating committee. Dr. Jackson is president of Jackson Associates, LLC, a biotechnology and pharmaceutical consulting company. Since September 2006, Dr. Jackson has also been president and chief executive officer of Ausio Pharmaceuticals, LLC, a drug development company. From May 2002 to May 2003, Dr. Jackson was president, chief executive officer and chairman of the board of directors of EmerGen, Inc., a biotechnology company. From November 1998 to January 2002, Dr. Jackson served as senior vice president, research and development for Atrix Laboratories, Inc., a biotechnology company. From January 1993 to July 1998, Dr. Jackson served as senior vice president, discovery research, at Wyeth Ayerst Laboratories, the pharmaceuticals division of American Home Products Corporation. Dr. Jackson’s qualifications for membership on the board of directors include over 20 years of experience in academic medicine and over 25 years of experience at several pharmaceutical and biotechnology companies, with positions in both research and development and senior management. This experience allows Dr. Jackson to provide board of directors with insights into the clinical development of product candidates. Dr. Jackson served as a director of Inflazyme Pharmaceuticals Ltd. until 2007. Dr. Jackson received his Ph.D. in microbiology and his B.S. in chemistry from the University of Illinois.
Daniel Spiegelman	Mr. Daniel K. Spiegelman is an Independent Director of Oncothyreon Inc. Mr. Spiegelman is the chairman of audit committee and a member of corporate governance and nominating committee. Mr. Spiegelman is the chief executive officer of Filtini Inc., a start-up company developing next generation circulating tumor cell capture and analysis technology. Mr. Spiegelman is also a co-founder and the chief financial officer of Rapidscan Pharma Solutions, Inc., a start-up company that has licensed the rights to sell regadenoson in Europe and other select territories. From 1998 to 2009, Mr. Spiegelman was employed at CV Therapeutics, Inc., a biopharmaceutical company acquired in 2009 by Gilead, most recently as senior vice president and chief financial officer. From 1992 to 1998, Mr. Spiegelman was an employee at Genentech, Inc., a biotechnology company, serving most recently as its treasurer. Mr. Spiegelman also serves as a member of the board of directors of Affymax, Inc., a biopharmaceuticals company, Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceuticals company, Omeros Corporation, a clinical-stage biopharmaceutical company, Anthera Pharmaceuticals, Inc., a development-stage biopharmaceutical company, and several private biopharmaceutical companies. Mr. Spiegelman’s qualifications for membership on the board of directors include his background in the financial and commercial issues facing growing biotechnology companies. Additionally, as chief financial officer of CV Therapeutics prior to its sale to Gilead Sciences, Mr. Spiegelman was involved in transitioning the company from a research and development focus to a commercial entity with two approved products. This experience allows Mr. Spiegelman to provide board of directors with insights into financial strategy and organizational development. Mr. Spiegelman received his B.A. and M.B.A. from Stanford University.
W. Vickery Stoughton	Mr. W. Vickery Stoughton is an Independent Director of Oncothyreon Inc. Mr. Stoughton is a member of audit and compensation committees. From August 2006 until September 2007, Mr. Stoughton served as president and chief executive officer of MagneVu Corporation, a medical devices company, which filed for bankruptcy in September 2007. From 1996 to 2002, Mr. Stoughton was chairman and chief executive officer of Careside Inc., a research and development medical devices company, which filed for bankruptcy in October 2002. From October 1995 to July 1996, Mr. Stoughton was president of SmithKline Beecham Diagnostics Systems Co., a diagnostic services and product company, and prior to October 1995 he served as president of SmithKline Beecham Clinical Laboratories, Inc., a clinical laboratory company. From 1988 until May 2008, Mr. Stoughton was a member of the board of directors of Sun Life Financial Inc., a financial services company. Mr. Stoughton’s qualifications for membership on the board of directors include his involvement in several medical device companies, his role as president of SmithKline Beecham Clinical Laboratories, and his broader business background. Through this experience, Mr. Stoughton provides board of directors with insights into the operational aspects of the company. Mr. Stoughton received his B.S. in chemistry from St. Louis University and his M.B.A. from the University of Chicago.
Douglas Williams	Dr. Douglas E. Williams is an Independent Director of Oncothyreon Inc. Dr. Williams serves as a member of audit committee. Since January 2011, Dr. Williams has served as the executive vice president of research and development at Biogen IDEC Inc., a publicly-traded biotechnology company. Dr. Williams joined ZymoGenetics, Inc. in 2004 and served as a director and chief executive officer from January 2009 until October 2010, when ZymoGenetics was acquired by Bristol-Myers Squibb. He has held senior level positions at a number of prominent biotechnology companies, including Biogen Idec, Seattle Genetics, Inc., Immunex Corporation, and Amgen, Inc. As executive vice president and chief technology officer at Immunex, Dr. Williams played a role in the discovery and early development of Enbrel, the first biologic approved for the treatment of rheumatoid arthritis. Dr. Williams’ qualifications for membership on the board of directors include over 20 years of experience in the biotechnology industry. During his career, Dr. Williams has been involved in the approval of three new protein therapeutics and in several label expansions. Further, through his experience as chief executive officer of ZymoGenetics, Inc., Dr. Williams provides board of directors with insights into the strategic and operational issues facing company. Dr. Williams currently serves as a director of Array BioPharma Inc., a biopharmaceutical company, and Aerovance, Inc., a privately-held biopharmaceutical company, and was director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, and Seattle Genetics, a clinical stage biotechnology company, until 2009 and 2005, respectively. Dr. Williams received a B.S. (magna cum laude) in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Cancer Institute Division.
Julie Rathbun

Basic Compensation

Name	Fiscal Year Total
Christopher Henney	203,000
Robert Kirkman	918,692
Julia Eastland	497,132
Gary Christianson	557,144
Scott Peterson	477,486
Diana Hausman	595,952
Richard Jackson	--
Daniel Spiegelman	--
W. Vickery Stoughton	--
Douglas Williams	--
Julie Rathbun	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Christopher Henney	0	0
Robert Kirkman	2,700,000	297,000
Julia Eastland	0	0
Gary Christianson	0	0
Scott Peterson	0	0
Diana Hausman	0	0
Richard Jackson	0	0
Daniel Spiegelman	0	0
W. Vickery Stoughton	0	0
Douglas Williams	0	0
Julie Rathbun	0	0

Insider Trading

Name	Shares Traded	Price
SPIEGELMAN DANIEL KEITH	8,174	$3.67
JACKSON RICHARD L	8,174	$3.67
WILLIAMS DOUGLAS E	8,174	$3.67
STOUGHTON W VICKERY	8,174	$3.67
HENNEY CHRISTOPHER S	8,174	$3.67
SPIEGELMAN DANIEL KEITH	2,021	$3.51
WILLIAMS DOUGLAS E	2,021	$3.51
HENNEY CHRISTOPHER S	2,021	$3.51
JACKSON RICHARD L	2,021	$3.51
STOUGHTON W VICKERY	2,021	$3.51
JACKSON RICHARD L	989	$0.00
HENNEY CHRISTOPHER S	989	$0.00
STOUGHTON W VICKERY	247	$4.15
HENNEY CHRISTOPHER S	247	$4.15
JACKSON RICHARD L	247	$4.15
STOUGHTON W VICKERY	989	$0.00
WILLIAMS DOUGLAS E	2,320	$0.00
HENNEY CHRISTOPHER S	2,388	$0.00
STOUGHTON W VICKERY	597	$7.58
HENNEY CHRISTOPHER S	597	$7.58
JACKSON RICHARD L	2,388	$0.00
JACKSON RICHARD L	597	$7.58
STOUGHTON W VICKERY	2,388	$0.00
HENNEY CHRISTOPHER S	1,546	$6.86
STOUGHTON W VICKERY	1,546	$6.86

» Full list on Insider Trading

People: Oncothyreon Inc (ONTY.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: